Patient derived xenograft

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Retrieved on: 
Monday, June 5, 2023
Graft-versus-host disease, HD, Antigen, DNA, BP, TRAC, HSPC, Euronext Growth, Interferon gamma, UGI, CD19, Red blood cell, ISCT, Lymphoid leukemia, CD20, Neoplasm, Thymine, Patient derived xenograft, Survival, Gene editing, Bone marrow, CD52, CD22, Deamination, Toxicity, Cell, Stem cell, PDX, CAR, Patient, Risk, Engineering, International Society, Knowledge, HBB, TALEN, TC, Phenotype, Vaccine, Online shopping, Cosmetics, HBSS, Cellectis, Cytosine

The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.

Key Points: 
  • The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
  • UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
  • The oral presentation highlighted the following preclinical data:
    Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
  • The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
    Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

AT&T Joins MyndVR's DigitalTherapyNow.org as Coalition Supporter to Promote Passage of Digital Therapeutics Bill

Retrieved on: 
Tuesday, March 21, 2023
Patient derived xenograft, AT&T, International, Therapy, AT, CA-05, Ageing, VR, Digital therapeutics, Congress, New York State Veterans' Home at Oxford, Digital, XRA, Health, National Association, Pharmaceutical industry, DALLAS

DALLAS, March 21, 2023 /PRNewswire/ -- MyndVR, the leading provider of therapeutic VR experiences designed for the aging population, today announced AT&T's support of the DigitalTherapyNow.org initiative. This purpose-driven alliance of academic and industry partners was designed to educate lawmakers in the effort to pass the bipartisan Access to Prescription Digital Therapeutics Act of 2023. AT&T stands alongside other industry leaders supporting this effort, including the XR Association (XRA), HTC, Select Rehabilitation, International VR Healthcare Association (IVRHA), and the National Association of State Veteran Homes (NASVH).

Key Points: 
  • America's most reliable 5G network joins academics and health advocates together in anticipating a technological shift in healthcare.
  • This purpose-driven alliance of academic and industry partners was designed to educate lawmakers in the effort to pass the bipartisan Access to Prescription Digital Therapeutics Act of 2023.
  • "As 10,000 Americans turn 65 every day, we know that digital therapeutics will play a critical role in reducing healthcare costs, while creating a new frontier in human health.
  • DigitalTherapyNow.org provides information, updates, resources and a growing petition to support the successful passing of the bill.

Lucius Partners Portfolio Company PD Theranostics, Inc. Signs Letter of Intent to Merge with Fulton Ventures Corp.

Retrieved on: 
Tuesday, March 7, 2023
Health, Patient derived xenograft, Brain, Prostate, LOI, PD, AI, Hospital, HIV disease progression rates, Commercial property

NEW YORK, March 7, 2023 /PRNewswire/ -- Lucius Partners, LLC today announced that its portfolio company, PD Theranostics, Inc. ("PDTx"), has signed a non-binding letter of intent (the "LOI") to combine with Fulton Ventures Corp. ("Fulton"), a company incorporated in British Columbia, Canada.

Key Points: 
  • NEW YORK, March 7, 2023 /PRNewswire/ -- Lucius Partners, LLC today announced that its portfolio company, PD Theranostics, Inc. ("PDTx"), has signed a non-binding letter of intent (the "LOI") to combine with Fulton Ventures Corp. ("Fulton"), a company incorporated in British Columbia, Canada.
  • The Proposed Transaction will be structured as a three-cornered amalgamation pursuant to an amalgamation agreement to be entered into between Fulton, a newly incorporated wholly-owned subsidiary of Fulton and PDTx.
  • After the closing of the Proposed Transaction, Fulton intends to file apply for listing on a recognized Canadian stock exchange in or around July 2023.
  • There can be no assurance that any such listing application will be made or that it will be successful.

BostonGene and Massachusetts General Hospital to Collaborate on Multiple Follicular Lymphoma Research Projects

Retrieved on: 
Tuesday, October 12, 2021
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Research, Software, Hospitals, Genetics, Science, Tumor microenvironment, Harvard Medical School, Follicular lymphoma, Patient derived xenograft, Doctor of Philosophy, Umbralisib, Department, B-cell lymphoma, Massachusetts General Hospital, Standard of care, Classification, Rituximab, Cancer, Population, MD, Â, MGH, Pathology, Aggressive lymphoma, Gene expression, Medicine, Patient, Neoplasm, PDX, NGS, Research, Biomarker, Economics, Pharmaceutical industry, Medical imaging

An indolent B-cell lymphoma, FL can transform into an aggressive lymphoma; however, the underlying causes of transformation remain unknown.

Key Points: 
  • An indolent B-cell lymphoma, FL can transform into an aggressive lymphoma; however, the underlying causes of transformation remain unknown.
  • BostonGene computational modeling of the molecular profiles of the primary patient FL tumors and the PDX tumors uncovers which patients may undergo transformation.
  • Were proud to collaborate with MGH by providing next-generation multi-platform analytics to evaluate the molecular and immunologic profiles of follicular lymphoma patients, said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
  • Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

Retrieved on: 
Tuesday, July 20, 2021
Cancer research, Medical specialties, Patient derived xenograft, Xenotransplantation, Clinical medicine, Pancreatic cancer, PDX, Pancreatic tumor, Medicine, Cancer, Mouse Models of Human Cancer database

platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced todaypositive new data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center .

Key Points: 
  • platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced todaypositive new data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center .
  • Preclinical data demonstrated that the drug candidate, LP-184, demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks.
  • Additional positive data on the efficacy and potency of LP-184 was gathered from 6 pancreatic cancer cell lines, and an additional 5 patient-derived xenograft (PDX) ex-vivo tumor models.
  • Analysis with Lantern's data platform, RADR, indicated that 35-40% of pancreatic cancer transcriptomes in clinical databases have elevated PTGR1 expression.

DGAP-News: DEFENCE THERAPEUTICS SIGNS A COLLABORATION AGREEMENT WITH THE CURIE INSTITUTE FOR TESTING THE ACCUM-T-DM1 ADC THERAPEUTIC IN PDX MODELS OF BREAST CANCER

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Cancer research, Patient derived xenograft, Xenotransplantation, Trastuzumab emtansine, Clinical medicine, PDX, Medical specialties, Breast cancer, Curie Institute

Vancouver, BC, Canada, June 29th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce the establishment of a collaboration with the Curie Institute (Paris, France) to evaluate the therapeutic efficacy of Accum-T-DM1 ADC in patient-derived xenograft (PDX) models of breast cancer.

Key Points: 
  • Vancouver, BC, Canada, June 29th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce the establishment of a collaboration with the Curie Institute (Paris, France) to evaluate the therapeutic efficacy of Accum-T-DM1 ADC in patient-derived xenograft (PDX) models of breast cancer.
  • Their scientific team has a wide expertise in the field of medical and experimental pharmacology with PDX models of cancer.
  • The agreement between the Curie Institute and Defence Therapeutics stipulates the following objectives related to the breast cancer:
    To perform a head-to-head toxicology profile comparisons of T-DM1 versus Accum-T-DM1 in mice.
  • Conduct a complete breast cancer efficacy study on PDX mice undergoing the ADC therapy, including in 3 HER2+ and in 1 triple-negative PDX.

Early Lung Cancer Coopts Immune Cell Into Helping Tumors Invade the Lungs, Mount Sinai Researchers Discover

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Immune system, Cell biology, Lymphatic system, Macrophage, Phagocytes, Cancer, Lung cancer, Cancer immunotherapy, Patient derived xenograft

The researchers found that early-stage lung cancer tumors coopt the immune cells, known as tissue-resident macrophages, to help invade lung tissue.

Key Points: 
  • The researchers found that early-stage lung cancer tumors coopt the immune cells, known as tissue-resident macrophages, to help invade lung tissue.
  • This process allows the tumor to hide from the immune system and proliferate into later, deadly stages of cancer.
  • In this study, scientists studied tissue samples from lung cancer tumors and surrounding lung tissue in 35 patients to see the role of macrophages in the development of the tumors.
  • Researchers identified the macrophages at play in the early development of lung cancer, identifying a potential target for future drug development.

Scientist.com Partners with Top CROs to Offer Disease Models for Cancer Research

Retrieved on: 
Tuesday, June 15, 2021
Science, Software, Research, Pharmaceutical, Oncology, Health, Data management, Technology, Branches of biology, Stem cells, Biology, Organoid, Tissue engineering, Life sciences, Xenotransplantation, Patient derived xenograft, Envigo

Scientists can filter by gene mutation, gene expression, cancer type or patient information, and then purchase without delay once the right model is identified.

Key Points: 
  • Scientists can filter by gene mutation, gene expression, cancer type or patient information, and then purchase without delay once the right model is identified.
  • The Disease Model Finder brings together a wealth of data that can help scientists choose the right preclinical disease models.
  • Marketplace customers can then filter their search results based on cancer type, subtype and characteristics or patient information.
  • By 2022, the platform will include other model systems including organoids, cell-derived xenografts (CDX), syngeneic models, immunoncology models and patient-derived cell lines.

BostonGene Announces Publication in Cancer Cell Revealing Four Tumor Microenvironment Subtypes Predict Response to Immunotherapy Across Multiple Cancers

Retrieved on: 
Thursday, May 20, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Branches of biology, Medicine, Clinical medicine, Biotechnology, Biomarker, Cell biology, Tumor microenvironment, Cancer treatments, Cancer, Patient derived xenograft, Tumour heterogeneity

\xe2\x80\x9cThe results of our study provided the foundation for us to launch BostonGene Tumor Portrait TestsTM, which are designed toidentify key drivers of each tumor, enabling doctors to personalize therapy for cancer patients.

Key Points: 
  • \xe2\x80\x9cThe results of our study provided the foundation for us to launch BostonGene Tumor Portrait TestsTM, which are designed toidentify key drivers of each tumor, enabling doctors to personalize therapy for cancer patients.
  • Transcriptomic data of over 10,000 cancer patients were analyzed, leading to the identification of four unique microenvironment subtypes that are conserved across 20 different cancers.
  • BostonGene Tumor Portrait TestsTM reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
  • Through these comprehensive analyses, BostonGene Tumor Portrait TestsTM generate a personalized roadmap for therapeutic decision-making for each cancer patient.

Eisai and National Cancer Center Commence Joint Research and Development Project

Retrieved on: 
Friday, May 14, 2021
Cancer, Eisai, Cancer research, Medicine, Clinical medicine, Health, Orphan drugs, Patient derived xenograft, Mouse Models of Human Cancer database

b'Using PDX With High Predictability of Clinical Outcomes, and Cancer Genome Data\nTOKYO, May 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement concerning "Basic research on the drug discovery and development to accelerate development of anticancer drugs in treatment of patients with rare cancers and refractory cancers", and that research activities have commenced.

Key Points: 
  • b'Using PDX With High Predictability of Clinical Outcomes, and Cancer Genome Data\nTOKYO, May 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement concerning "Basic research on the drug discovery and development to accelerate development of anticancer drugs in treatment of patients with rare cancers and refractory cancers", and that research activities have commenced.
  • Also, among certain types of cancer with a large number of patients, refractory cancers, for which standard treatment has not been established, face barriers to creating new drugs due to difficulty of research and development.
  • As of May 2020, with a grant from AMED CiCLE, the National Cancer Center has established a large-scale PDX library,"J-PDX", derived from Japanese cancer patients with information on clinical outcomes, and has also completed the development of research infrastructure and framework.
  • More than 410 types of PDX, including rare cancers and refractory cancers, have already been established in J-PDX (as of March 2021).\nIn research and development under the agreement, Eisai and the National Cancer Center will jointly conduct tumor-agnostic non-clinical research on new drug candidates created by Eisai, using J-PDX with relevant clinical and biological information, and will determine the drugs and the target cancer types to be transferred to clinical studies.